The concept of foot orthotic dosing has been having some more recognition in recent years. It is actually in line with the analogy of drugs dosage. Everyone who might be on a different drug or prescription medication for any medical problem ought to essentially taking a specific measure or quantity of that medication. Precisely the same ought to be the scenario pertaining to foot orthotics. A distinct “dose” of foot supports should be used. All too often foot supports are all given the identical dosage of foot supports, particularly in studies or research. An episode of the monthly podiatry live show, PodChatLive hammered out this matter. The hosts of the livestream chatted with Simon Spooner in order to focus on some of the limitations of foot orthotics research in accordance with the idea. They talked about the way in which clinicians should be watching all conclusions from research made in the framework of these constraints. They talked about as to what “perfect” foot orthotic research could look like, the points we might choose to ‘measure’ and the apparent discussion between the lab and the clinic. Most significantly they reviewed exactly what ‘foot orthotic dosing’ is, and how it will help us answer concerns that are at present unanswered.
Dr Simon Spooner graduated as a Podiatrist in 1991 graduating from the University of Brighton, and in addition to his BSc in Podiatry, he was awarded the Paul Shenton prize for his research into callus. Then he continued to complete his PhD in Podiatry from the University of Leicester in 1997, where he examined the reasons and management of inherited foot disorders. Simon is currently the Director of Podiatry at Peninsula Podiatry. His practice expertise include sports medicine, foot orthotics, and children as well as adult foot and gait irregularities. As well as his own clinical work, he has produced a variety of research papers on podiatric care and has delivered papers at both national and international meetings, and presented postgraduate education for a variety of NHS Trusts.